CompletedNCT04818086
Lemborexant with buprenorphine and naloxone: safety and drug interactions
About this title
Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
Read the official source — NCT04818086Medication studyAges 18–65United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- RichmondSee all locations and recruitment
- Participation duration
- About 4 weeks
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateStarted: May 3, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 18
- Sponsor
- Virginia Commonwealth University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04818086
- Official title
Show the full official title
Phase Ib/2a Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Richmond
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Virginia Commonwealth University, a university.
Did this study involve medication?
Yes. The study involved medication, including Lemborexant, Placebo and Buprenorphine-naloxone.
Who was this study for?
Listed age limits: 18 years to 65 years.
